- Company Continues Leadership Through Software, Services and Education - DENVER, Oct. 11 /PRNewswire-FirstCall/ -- Wyndgate Technologies(R), a division of Global Med Technologies(R), Inc., (OTC:GLOB) (BULLETIN BOARD: GLOB) is furthering its leadership in the blood industry by offering expert software and services to help its clients adopt the international standard for blood component labeling, known as ISBT 128. (Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) ISBT 128 sets a global standard for blood component labeling and enables blood products to be managed and shared around the world. The standard revolutionizes the information contained in a blood component label, allowing for unique identification of any donation worldwide. This identification number allows a blood component to be traced back to its donor of origin regardless of where it may be transfused. In addition, the labeling standard relays critical information regarding each blood component in a secure electronic format to help prevent accidental misuse with blood products from multiple countries or facilities. In effect, ISBT 128 enables blood products collected in one location to be safely transfused across borders, governments and healthcare systems. The impact of this standard for multinational disaster relief programs, widespread military operations and building international data stores is significant. Wyndgate Technologies recognized the potential impact of the international standard on the blood industry early in its introduction and has supported the standard in its blood software products since 1999. The ISBT 128 blood labeling standard has been gaining attention around the world during the past few years, although a requirement only recently emerged in the United States mandating that the standard be adopted. With the new U.S. requirement, Wyndgate has seen an increased demand for ISBT 128 education and services. In an effort to assist its customers to adopt the standard, Wyndgate has developed an online educational series and has begun providing consulting services regarding implementing the standard. More than 500 individuals have attended one or more of the online education sessions that the company presented this year. Wyndgate will continue to offer additional ISBT 128 education sessions and services. "The ISBT 128 initiative is a substantial step for patient safety and for allowing blood products to be shared worldwide," stated Michael I Ruxin, M.D., Chairman and CEO of Global Med Technologies. Dr. Ruxin continued, "This standard has the potential to change the way the U.S. and the world respond to emergencies, disasters and patients' needs by increasing access to blood products and the information to use the products safely. Wyndgate saw a need in the industry and among our clients for software, education and assistance regarding ISBT 128. In order to further enhance our leadership role in the blood bank and hospital transfusion software industry, the company moved forward to fulfill those needs." About Global Med Technologies, Inc. Global Med Technologies, Inc. is an international e-Health, medical information technology company, providing information management software products and services to the healthcare industry. Its Wyndgate Technologies division is a leading supplier of information management systems to U.S. and international blood centers and hospital transfusion centers. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Wyndgate's products are being used in Canada and sub-Saharan Africa, and are being implemented in the Caribbean. Together, the SafeTrace Tx(R)* advanced transfusion management system and the SafeTrace(R) donor management system provide Vein-to-Vein(R) tracking from donor collection to patient transfusion. For more information about Global Med's products and services, please call 800-WYNDGATE or visit http://www.globalmedtech.com/, http://www.peoplemed.com/ and http://www.wyndgate.com/. This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release. * Patent Pending http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies, Inc. CONTACT: Michael I. Ruxin, M.D., Global Med Technologies, Inc., +1-303-238-2000 Web site: http://www.globalmedtech.com/ Web site: http://www.peoplemed.com/ Web site: http://www.wyndgate.com/ Web site: http://www.globalmedtech.com/

Copyright